A 2020 in vitro study by Wang et al. showed that when used in combination with decitabine, a DNMT inhibitor, entinostat, exhibited a cytotoxic effect on chemoresistant bladder cancer cells without damaging normal urothelial cells [80]. This evidence concerns the gene DNMT1 and urinary bladder carcinoma.